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A BS T R AC T
BACKGROUND

Outcomes in children and adolescents with recurrent or progressive high-grade
glioma are poor, with a historical median overall survival of 5.6 months. Pediatric
high-grade gliomas are largely immunologically silent or “cold,” with few tumorinfiltrating lymphocytes. Preclinically, pediatric brain tumors are highly sensitive
to oncolytic virotherapy with genetically engineered herpes simplex virus type 1
(HSV-1) G207, which lacks genes essential for replication in normal brain tissue.

The authors’ full names, academic degrees, and affiliations are listed in the
Appendix. Address reprint requests to Dr.
Friedman at the Department of Pediatrics, University of Alabama at Birmingham, 1600 7th Ave. S., Lowder 512, Birmingham, AL 35233, or at g friedman@
peds.uab.edu.

METHODS

This article was published on April 10,
2021, at NEJM.org.

We conducted a phase 1 trial of G207, which used a 3+3 design with four dose
cohorts of children and adolescents with biopsy-confirmed recurrent or progressive
supratentorial brain tumors. Patients underwent stereotactic placement of up to
four intratumoral catheters. The following day, they received G207 (107 or 108 plaqueforming units) by controlled-rate infusion over a period of 6 hours. Cohorts 3 and 4
received radiation (5 Gy) to the gross tumor volume within 24 hours after G207
administration. Viral shedding from saliva, conjunctiva, and blood was assessed
by culture and polymerase-chain-reaction assay. Matched pre- and post-treatment
tissue samples were examined for tumor-infiltrating lymphocytes by immunohistologic analysis.
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RESULTS

Twelve patients 7 to 18 years of age with high-grade glioma received G207. No
dose-limiting toxic effects or serious adverse events were attributed to G207 by the
investigators. Twenty grade 1 adverse events were possibly related to G207. No virus
shedding was detected. Radiographic, neuropathological, or clinical responses were
seen in 11 patients. The median overall survival was 12.2 months (95% confidence
interval, 8.0 to 16.4); as of June 5, 2020, a total of 4 of 11 patients were still alive
18 months after G207 treatment. G207 markedly increased the number of tumorinfiltrating lymphocytes.
CONCLUSIONS

Intratumoral G207 alone and with radiation had an acceptable adverse-event profile with evidence of responses in patients with recurrent or progressive pediatric
high-grade glioma. G207 converted immunologically “cold” tumors to “hot.” (Supported by the Food and Drug Administration and others; ClinicalTrials.gov number,
NCT02457845.)
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alignant high-grade glioma accounts for 8 to 10% of pediatric brain
tumors and is regularly fatal, with a
rapid course. Survival rates have not improved in
30 years; the 3-year event-free survival among
patients with newly diagnosed tumors who are
treated with standard radiation and chemotherapy is 11 to 22%.1,2 At recurrence, the median life
expectancy is only 5.6 months.2,3 For the few
children cured of high-grade glioma, conventional therapies can irreversibly injure the developing brain.4 The lack of progress in developing
an effective immunotherapy for pediatric highgrade glioma is attributable to several factors:
low somatic mutational burden, leading to limited neoantigens and actionable alterations; intertumoral and intratumoral heterogeneity; immunologically “cold” and silent tumors with few
tumor-infiltrating lymphocytes; and drug-delivery
challenges due to the blood–brain barrier.4,5
We investigated genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) G207,
which has the potential to overcome many treatment challenges posed by pediatric high-grade
glioma. G207 contains deletion of the diploid
γ134.5 neurovirulence gene and has viral ribonucleotide reductase (UL39) disabled by insertion
of Escherichia coli lacZ.6 These mutations prevent a
productive infection of normal cells while permitting conditional replication in tumor cells (see
the Methods section in the Supplementary Appendix, available with the full text of this article
at NEJM.org).7,8 G207 is neurotropic, making brain
tumors ideal targets. It can be inoculated intratumorally to circumvent the blood–brain barrier,
and it is easily detected (lacZ reporter gene) and
hypersensitive to antiviral drugs owing to a retained thymidine kinase gene. In addition to infecting and lysing tumor cells directly, G207 can
reverse tumor immune evasion, increase crosspresentation of tumor antigens, and promote an
antitumor immune response even in the absence
of virus permissivity.9-12 A single radiation dose
enhances G207 efficacy in animal models by increasing viral replication and spread.13
In trials involving adults with high-grade
glioma, G207 was safe when inoculated intratumorally, into brain surrounding tumor resection cavities, and combined with a single radiation
dose.14-16 In preclinical studies, pediatric murine
and patient-derived xenograft brain-tumor models, including cancer stem cells, were highly
1614
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sensitive to oncolysis by G207.17-20 Pediatric brain
tumors were 11 times as sensitive as adult glioblastoma xenografts, a finding that suggests
that children are ideal candidates for G207.17
Together, these data provided a strong rationale
for conducting a trial involving children and
adolescents and informed our scientific hypothesis that intratumoral G207 would increase the
amount of tumor-infiltrating lymphocytes and
thereby convert immunologically “cold” pediatric
brain tumors to “hot” and “inflamed.” Herein,
we report the results of a phase 1 trial of G207
immunovirotherapy in children and adolescents
with high-grade glioma.

Me thods
Objectives

The primary objective was to evaluate the safety
and adverse-event profile of intratumoral G207
alone or combined with a single 5-Gy radiation
dose in children and adolescents with recurrent or
progressive malignant supratentorial brain tumors. The secondary objective was to assess for
potential efficacy and biologic response to G207
by measuring radiographic response, progressionfree and overall survival, performance score,
immune response, and the occurrence of G207
viremia or shedding.
Patient Population

Children and adolescents (3 to 18 years of age)
with a pathologically proven malignant supratentorial brain tumor with a diameter of 1.0 cm
or more that progressed after surgery, radiotherapy, or chemotherapy were eligible. Full recovery
from acute toxic effects from previous therapy
with suitable hematologic, renal, and liver function and a Karnofsky or Lansky performance
score of 60 or more (on a scale from 0 to 100,
with higher scores indicating better function)
were required, as described in the inclusion and
exclusion criteria (Table S1 in the Supplementary
Appendix). Patients with tumors that would require cerebellar, brain-stem, or ventricular inoculation were excluded.
Trial Design and Oversight

The investigator-initiated trial was approved by
institutional review boards at the University of
Alabama at Birmingham (UAB) and Nationwide
Children’s Hospital and was conducted under a
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Food and Drug Administration (FDA) Investigational New Drug application in accordance with
International Council for Harmonization Good
Clinical Practice guidelines. The trial began at
the UAB in May 2016, and Nationwide Children’s
Hospital was added as a trial site in 2019 to
confirm the feasibility of treatment at a different institution. The open-label, nonrandomized
phase 1 trial used a 3+3 design (see the Methods
section in the Supplementary Appendix) with
four dose cohorts: 107 plaque-forming units
(PFU), 108 PFU, 107 PFU with 5 Gy of radiation,
and 108 PFU with 5 Gy of radiation. The G207
dose was not escalated further, on the basis of
data from the phase 1 trial involving adults,
which indicated that responses were not dosedependent and in which participants with the
longest survival received 107 or 108 PFU.14 Stopping rules included establishment of the maximum tolerated or planned dose or unacceptable
toxic effects at the lowest proposed dose.
The first author, trial coordinator, and UAB
Clinical Trials Network and Monitoring Office
Manager continuously monitored safety and data
for all the patients. The UAB Clinical Trials
Monitoring Committee met approximately monthly to provide oversight and to serve as the data
and safety monitoring committee, as part of the
UAB O’Neal Comprehensive Cancer Center Data
and Safety Monitoring Plan. The first author,
trial coordinator, and authors with expertise in
neurosurgery, radiology, neuropathology, and immunology tabulated and analyzed the data. A bio
statistician with expertise in clinical trials confirmed the accuracy of the data and analyses.
The first author wrote the first draft of the
manuscript, and all the authors participated in
the manuscript writing, reviewing, and editing
and agreed with the contents. All the authors
vouch for the completeness and accuracy of the
data and for adherence of the trial to the protocol, available at NEJM.org. There were no confidentiality agreements related to the data between
the authors, any institutions, or Aettis/Treovir,
which provided the trial drug only and participated in editing an earlier version of the manuscript but not in writing the manuscript or in
analyzing the data.
Parents, guardians, or patients provided written informed consent and patients 7 to 13 years
of age provided assent before screening and
treatment. After confirmation of the tumor by
n engl j med 384;17

stereotactic biopsy and of satisfactory intratumoral catheter locations by computed tomography (CT) the next morning, G207 was inoculated
over a period of 6 hours in 2.4 ml total volume.
In two of the dose cohorts, the gross tumor
volume plus 2-mm margins received 5 Gy of radiation within 24 hours after G207 administration. Patients were monitored in the hospital for
3 days after G207 administration and in outpatient clinics while enrolled in the trial. HSV-1
serologic status was determined by immunofluorescence assay. G207 shedding from saliva, conjunctiva, and blood was assessed by culture and
polymerase-chain-reaction (PCR) assay. Serial
complete blood counts with quantitative lymphocyte subsets were obtained. Matched pre- and
post-treatment tissue samples were examined
for tumor-infiltrating lymphocytes by immunohistologic analysis. (For more on trial design
and oversight, see the Methods section in the
Supplementary Appendix.)
Safety Evaluation

Patients were continuously monitored for toxic
effects and adverse events, which were graded
according to the Common Terminology Criteria
for Adverse Events, versions 4.03 to 5.0. Doselimiting toxic effects were defined as any grade 3
or 4 toxic effect possibly related to G207 within
30 days after G207 administration. Owing to the
possibility of pseudoprogression (a well-known
occurrence in oncolytic virotherapy, other immunotherapies, and the treatment of malignant
brain tumors21,22), neurologic changes were treated with the supportive care agents bevacizumab,
glucocorticoids, or both at the discretion of
the investigator. A reduction in symptoms with
supportive care was not considered to be doselimiting.
Response Assessment

Magnetic resonance imaging (MRI) was performed at screening, day 3, and outpatient visits
starting at day 28. Acquired imaging sequences
are outlined in the protocol. No generally accepted, well-defined criteria for measuring response
after intratumoral immunovirotherapy exist; apparent tumor enlargement may be seen that can
be associated with new or enlarging central tumor cavities or cysts from tumor-cell death,
inflammation related to an influx of immune
cells (pseudoprogression), or delayed antitumor
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1 Did not meet eligibility
criteria

Safety Outcomes

3 Received 107 PFU of G207
3 Received 108 PFU of G207
3 Received 107 PFU of G207+5 Gy of radiation
3 Received 108 PFU of G207+5 Gy of radiation

12 Were included in the analysis

Figure 1. Enrollment, Treatment, and Analysis.
PFU denotes plaque-forming units.

immune responses.23-25 Radiographic response
was determined primarily according to immunotherapy Response Assessment in Neuro-Oncology
(iRANO) criteria, despite their limitations.26
Statistical Analysis

Adverse events were summarized according to
frequency, grade, and relation to G207. Descriptive statistics were tabulated on HSV-1 serologic
status, G207 shedding, radiographic response,
and performance score. Overall survival was defined as the time from G207 infusion to death.
The median overall survival was calculated and
Kaplan–Meier survival curves generated with the
use of SigmaPlot, version 12.0 (Systat Software).

R e sult s
Patient Characteristics

Between October 2016 and April 2020, a total of
13 patients were screened, and 12 (6 male patients and 6 female patients; age range, 7 to 18
years) (Table S2) with progressive or recurrent
supratentorial high-grade glioma received G207
after biopsy specimens showed tumor presence
(Fig. 1). Tumor classifications included 10 glioblastomas, 1 anaplastic astrocytoma, and 1 highgrade glioma, not otherwise specified. All tumors
were IDH wild-type (Table S3). Ten tumors were
large, with a bi-perpendicular sum of 5.5 cm or
more at screening. Three tumors were multi
focal, and 1 had leptomeningeal spread. The
majority of patients were heavily pretreated; be-

n engl j med 384;17
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fore G207 administration, 8 patients had at least
two previous failed treatments and 4 had at least
three previous failed treatments. Performance
scores ranged from 70 to 100 before G207 administration (Table S4).

13 Patients were assessed for eligibility

1616

of

Three catheters (in 4 patients) or 4 catheters
(8 patients) were safely placed throughout the
cerebrum, including the thalamus, insula, corpus
callosum, and the frontal, parietal, temporal, and
occipital lobes. Of 44 catheters placed, 2 (5%)
were retracted at the bedside into a suitable position by the neurosurgeon before G207 infusion,
and one (2%) was not used because of proximity
to the ventricle. No neurologic sequelae from the
surgical procedures were noted. Two minor complications were attributed by the investigators to
the neurosurgery: a small catheter tract hemorrhage noted on a CT scan before G207 infusion
that did not warrant intervention, and a cerebrospinal fluid leak from the initial biopsy and
catheter placement site that required oversewing
on day 8.
G207 delivery was not associated with grade
3 or 4 toxic effects in any patients, including at
the maximum planned dose (108 PFU plus 5 Gy
of radiation). Eleven of 12 patients had at least
one adverse event that was possibly related to
G207; however, all 20 adverse events were of
grade 1 (Table S5). Table 1 lists the cumulative
incidence of all adverse events within 30 days
after G207 administration. Tables S6 and S7 list
adverse events for each patient who received
G207 alone or with radiation. No dose-limiting
toxic effects or serious adverse events (Table S8)
were attributed to G207 by the investigators.
Furthermore, no patient had evidence of peripheral G207 shedding or viremia. One patient who
was HSV-1 seropositive before receiving G207
had a positive saliva HSV PCR assay at day 28;
however, it was negative for lacZ and G207 sequences, and this negative result confirmed reactivation of wild-type HSV-1 (see the Methods
section in the Supplementary Appendix).
Treatment Outcomes

Radiographic, neuropathological, or clinical responses were seen in 11 patients. The median
overall survival among patients who were treated
with G207 was 12.2 months (95% confidence
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interval [CI], 8.0 to 16.4); as of June 5, 2020, a
total of 4 of 11 patients (36%) were still alive 18
months after G207 treatment (Fig. 2). As with
other immunovirotherapies,23 determination of
the timing of progression was difficult owing to
pseudoprogression and mixed responses except
when disease was stable (see Table S4 for the
time that each patient met iRANO criteria for
progression). At initial evaluation, two types of
imaging responses were seen: stable appearance
and pseudoprogression. Stable disease was seen
in 7 of 12 patients (58%) at 1 month, in 4 of 11
patients (36%) at 3 months, in 3 of 11 patients
(27%) at 5 months, and in 2 of 11 patients (18%)
at 12 months. Imaging from Patient 002 (Fig. 3)
and Patient 005 (Fig. S1) showed stable disease.
The tumor of Patient 002 was stable through
3 months; by 5 months, polycystic degradation
(“Swiss cheese” appearance) was apparent. The
number and size of cysts increased over time
and corresponded with an increase in the performance score from 80 before treatment to 100
at 12 months after treatment. Similarly, cystic
changes developed in the tumor of Patient 005,
who had stable disease through 12 months after
G207 treatment. In contrast, imaging from Patient 007 showed pseudoprogression (Fig. S2).
The patient was asymptomatic and had an unremarkable physical examination; these clinical
findings were consistent with pseudoprogression. A biopsy that was performed 3 months
after G207 treatment to clarify imaging findings
revealed semiliquified, friable tissue with residual tumor cells.
In four patients who had undergone a posttreatment biopsy or resection owing to indeterminate MRI findings (three patients) or newonset neurologic symptoms (one patient), we
assessed matched pre- and post-treatment tissues for T lymphocytes by immunohistochemical
analysis (see the Methods section in the Supplementary Appendix). Pretreatment tissue had few
tumor-infiltrating lymphocytes, as expected for
pediatric high-grade glioma. In contrast, tissue
2 to 9 months post-treatment from patients in
each dose cohort revealed substantive increases
in CD3+, CD4+, and CD8+ tumor-infiltrating
lymphocytes. (Fig. S3 shows quantification and
Table S9 shows differences in median positive
cells between the pretreatment and post-treatment tissue samples.) Clusters of CD8+ (Fig. 4)

n engl j med 384;17

Table 1. Adverse Events in the 12 Patients.*
Event

Cardiac disorders
Bradycardia
Hypertension
Hypotension
Tachycardia
Ear and labyrinth disorders: external
ear inflammation
Gastrointestinal disorders
Abdominal pain
Constipation
Diarrhea
Nausea
Vomiting
General disorders
Chills
Fatigue
Fever
Blood and lymphatic system: anemia
Infections and infestations: perirectal
abscess
Procedural complications: post
operative hemorrhage
Investigations
Increased ALT level
Increased AST level
Decreased lymphocyte count
Decreased neutrophil count
Decreased platelet count
Weight loss
Decreased white-cell count
Metabolism and nutrition
Anorexia
Hyperphosphatemia
Obesity
Nervous system disorders
Cerebrospinal fluid leak
Dizziness
Facial nerve disorder
Headache
Peritumoral vasogenic edema
Seizure
Skin disorders: contact dermatitis
Total

Grade 1 Grade 2 Grade 3

Total

no.

no. (%)

2
1
1
1
0

0
0
0
0
1

0
0
0
0
0

2 (17)
1 (8)
1 (8)
1 (8)
1 (8)

1
1
3
2
3

0
0
0
0
2

0
0
0
0
0

1 (8)
1 (8)
3 (25)
2 (17)
5 (42)

1
3
4
1
0

0
0
0
0
0

0
0
0
1
1

1 (8)
3 (25)
4 (33)
2 (17)
1 (8)

6

0

0

6 (50)

0
0
0
1
3
1
0

1
2
0
0
0
0
1

1
0
1
1
0
0
1

2 (17)
2 (17)
1 (8)
2 (17)
3 (25)
1 (8)
2 (17)

2
1
0

0
0
0

0
0
1

2 (17)
1 (8)
1 (8)

0
1
1
2
0
2
1
45

1
0
0
1
1
0
1
11

0
0
0
0
0
0
0
7

1 (8)
1 (8)
1 (8)
3 (25)
1 (8)
2 (17)
2 (17)
63

*	Shown is the cumulative incidence of adverse events according to highest
grade irrespective of cause within 30 days after G207 administration. There
were no events of grade 4. ALT denotes alanine aminotransferase, and AST
aspartate aminotransferase.
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post-treatment (Fig. S6). No evidence of HSV-1
staining was seen in any post-treatment tissue,
which indicated that G207 was no longer replicating or present (Fig. S7). Assessment of CD20+
B lymphocytes (Fig. S8) and CD138+ plasma
cells (Fig. S9) in Patients 006, 009, and 010 by
immunohistochemical analysis revealed few pretreatment CD20+ or CD138+ cells (Fig. S3).
However, post-treatment, CD20+ cells were increased in Patient 009, and CD138+ cells were
increased in Patients 009 and 010 (Table S9).

1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

of

0

4

8

12

16

20

40

44

Immune Responses in Blood, Post-G207
Supportive Care, and Other Treatments

Months since Receiving G207
No. at Risk
12
No. with Censored 0
Data
No. of Events
0

10
1

8
1

6
1

4
1

1
2

1
2

0
3

1

3

5

7

9

9

9

Figure 2. Kaplan–Meier Curve of Overall Survival Probability among Patients
Treated with G207.
The median survival was 12.2 months (95% confidence interval, 8.0 to 16.4).
Circles represent patients with censored data.

and CD4+ (Fig. S4) tumor-infiltrating lymphocytes were observed after G207 treatment. In
Patient 009, T cells infiltrated throughout the
resected tumor in areas adjacent to and distant
from where G207 was inoculated 5 months earlier (Fig. S5). In Patient 010, tumor-infiltrating
lymphocytes increased between 2 and 3 months
Before Treatment

1 Month

5 Months

We considered that previous infection with HSV-1
might interfere with the efficiency of G207 infection owing to neutralizing antibodies, and we
deemed seroconversion as measurable confirmation of an immune response to G207 infection.27
The median overall survival among patients with
baseline HSV-1 IgG antibodies (three patients)
was 5.1 months (95% CI, 3.0 to 7.2), as compared with 18.3 months (95% CI, 9.2 to 27.4)
among patients who had seroconversion after
G207 (three patients) (Table S10). No patients
had seroconversion after treatment with 107 PFU.
Table S11 summarizes peripheral white-cell
counts and absolute neutrophil, lymphocyte,
natural killer (NK) cell, and T-lymphocyte counts
at baseline as well as activated T-cell counts and
9 Months

12 Months

24 Months

Figure 3. Response in Patient 002 Treated with G207.
In the top row, post-gadolinium sagittal T1-weighted images show the decreased size of the enhancing component
of the tumor with interval development of numerous enlarging cystic spaces where G207 was inoculated. In the bottom row, sagittal fluid-attenuated inversion recovery (FLAIR) images show an interval decrease in the size of the
FLAIR hyperintense component of the tumor in the frontal and temporal lobes after G207 treatment. These changes
corresponded with an increase in the performance score from 80 before treatment to 100 by 12 months after treatment
(on a scale from 0 to 100, with higher scores indicating better function). The patient had a continuous response
42 months after G207 treatment without any additional therapy.
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CD4:CD8 ratios at baseline and on days 7, 14,
and 28. Six patients had lymphopenia at baseline. Despite having severe lymphopenia before
G207 treatment, Patient 010 had a sizeable infiltration of tumor with lymphocytes after G207
treatment (Fig. S6). NK cells are important in
controlling herpesvirus infections in humans and
may contribute to antitumor immunity.28 When
patients who were seropositive before treatment
were excluded, baseline levels of absolute NK
cells correlated positively with survival (Spearman’s rank correlation coefficient, 0.81 for all
patients and 0.88 for patients who had died)
(Fig. S10). Table S4 summarizes supportive care
with glucocorticoids (three patients) and bevacizumab (six patients) and subsequent treatments received after G207 treatment (eight patients).

Patient No.
and Dose

Discussion
Pediatric high-grade glioma is a devastating disease that lacks effective, targeted therapies and
results in high morbidity and mortality. Several
promising cancer-selective immunovirotherapy
approaches are in various stages of clinical development to target high-grade glioma in both
adults and children. Replication-deficient viruses
are being tested to deliver enzymes (e.g., cytosine deaminase and thymidine kinase) to tumor
cells to convert prodrugs to active cytotoxic
agents and induce gene-mediated cytotoxic immunotherapy29 or to produce cytokines (e.g., interleukin-12) locally when in the presence of a
small-molecule activator to overcome the immunosuppressive microenvironment of high-grade
glioma.30 Several replication-competent viruses,

Before Treatment
Low magnification

Time since
Receiving G207

After Treatment
Low magnification

Medium magnification

High magnification

Patient 001:
107 PFU

3 Months
150 µm

150 µm

100 µm

50 µm

Patient 006:
108 PFU

9 Months
150 µm

150 µm

100 µm

50 µm

Patient 009:
107 PFU
+5 Gy

5 Months
150 µm

150 µm

100 µm

50 µm

Patient 010:
108 PFU
+5 Gy

3 Months
150 µm

150 µm

100 µm

50 µm

Figure 4. Immunohistologic Staining for CD8+ Cytotoxic T Lymphocytes in Matched Pre- and Post-treatment Tissue from Four Patients.
The left column shows the initial core biopsies before G207 administration; there were few immune-related cells, a finding consistent
with immunologically silent or “cold” tumors. The other three columns show tumor tissues between 3 and 9 months after G207 administration from these same four patients. Post-G207 tissue revealed a brisk infiltration of CD8+ cells, which indicates an immune response
to G207 and a shift to immunologically “hot” tumors. Photomicrographs were taken at low, medium, and high magnifications. Doses
are in plaque-forming units (PFU) of G207 and in grays (Gy) of radiation.
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both unmodified (e.g., reovirus) and genetically
engineered for tumor selectivity (e.g., herpesvirus,
poliovirus, adenovirus, and measles virus),31 are
being investigated in malignant pediatric brain
tumors.
In this phase 1 immunovirotherapy trial involving children and adolescents with high-grade
glioma, genetically engineered herpesvirus G207
alone and with radiation elicited only low-grade
toxic effects. Side effects that were attributed to
G207 were mild and manageable with observation or supportive care. As in previous trials of
G207 involving adults with high-grade glioma,14-16
no evidence of peripheral viral shedding was
found. Most patients had a strong response to
G207 despite many being heavily pretreated and
having large tumors. Studies in melanoma that
used FDA-approved oncolytic HSV-1 talimogene
laherparepvec showed that the virus initiates delayed regional and systemic antitumor immune
responses ranging from 18.4 to 29.1 weeks.25
Thus, unlike traditional therapies, patients may
benefit from G207 months after receiving it even
after another therapy is initiated, resulting in
improved overall survival. The median overall
survival of 12.2 months (95% CI, 8.0 to 16.4)
among patients who received G207 is very promising. Although our phase 1 trial involving 12
patients cannot be compared directly with previous studies, the median overall survival among
patients with pediatric high-grade glioma at
initial progression after front-line therapy in the
Children’s Oncology Group ACNS0423 study was
only 5.6 months (95% CI, 4.3 to 7.2).2 This median value was confirmed in a recent metaanalysis of 17 studies involving pediatric patients with recurrent high-grade glioma (overall
survival, 5.6 months; 95% CI, 3.9 to 7.3).3 In
addition, 4 patients in the current trial who received G207 have lived past 18 months thus far,
which exceeds the median overall survival among
pediatric patients with newly diagnosed hemispheric high-grade glioma.5 These encouraging
results will need to be confirmed in an upcoming phase 2 trial.
We found that seroconversion after G207
treatment occurred only in patients who received
the 108-PFU dose, which indicates that seroconversion is dose-dependent when virus is inoculated in the brain. Preexisting antibodies reduced
median overall survival by nearly half in studies
of oncolytic adenovirus involving adults with
1620
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solid tumors, whereas seropositivity did not reduce the efficacy of oncolytic HSV-1 talimogene
laherparepvec in patients with melanoma.22,27
However, patients received an initial 106-PFU
dose of talimogene laherparepvec followed by
subsequent 108-PFU doses, which probably diminished the ability to detect any effect of preexisting neutralizing antibodies on response.22
Although 70 to 90% of adults have preexisting
HSV-1 antibodies, most children are seronegative.32 Further assessment of the usefulness of
baseline HSV-1 seropositivity and seroconversion
as a biomarker of treatment response in children
is needed.
On the basis of the neuropathological data,
we surmise that responses seen in this trial were
immune-mediated. G207 results in a dramatic
increase in tumor-infiltrating lymphocytes. It is
uncertain whether tumor-infiltrating lymphocytes seen 2 to 9 months after treatment were
tumor-specific. However, they may have had
an antitumor role. Active HSV infection is selflimited in immunocompetent hosts.33 In animals,
wild-type HSV replication peaks at approximately
5 days, followed by abrogation by CD8+ T cells
within approximately 10 days.33,34 Likewise, preclinical studies indicate that G207 infection is
eliminated within a similar period.9,10 G207 has
greatly diminished capacity to establish latency
because a portion of latency-activated transcripts
is affected by γ134.5 gene deletions.34 Although
a small amount of G207 DNA may persist several
months after G207 treatment,14 antiviral T cells
respond to virus-derived peptides and not DNA.
In preclinical studies, G207 induced cytotoxic
T-lymphocyte antitumor responses within 20 days
and resulted in antitumor immunity.9,10
The matched pre- and post-treatment tumor
tissues are suggestive of antitumor T-cell responses. Clusters of T cells were seen up to 9 months
after G207 treatment without evidence of HSV-1
staining. The tissue showed an ongoing T-cell
infiltration that increased over time and was
detected in distant areas several centimeters
from G207 inoculation. T-cell receptor sequencing was not performed. Although rare subtypes
of pediatric high-grade glioma may respond to
immunotherapy (e.g., hypermutated),35 pediatric
high-grade gliomas are largely immunologically
silent. The informative difference in this trial is
the large number of tumor-infiltrating lymphocytes induced by intratumoral G207 inoculation,
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although it remains unclear whether the infiltrates reflect a general inflammatory response
or the response is indeed related to virus antigen
or tumor antigen recognition.
We found that G207 alone and with radiation
was associated with mainly low-grade toxic effects, with evidence of responses in many of the
children. G207 converted immunologically “cold”
tumors to “hot,” with high numbers of infiltrating T cells and other inflammatory cells. To extend and confirm the findings in this phase 1
trial, a multi-institutional phase 2 clinical trial of
G207 in pediatric high-grade glioma (ClinicalTrials
.gov number, NCT04482933) is forthcoming.
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